☰

Anthony W. Gebhard, Ph.D. - Publications

Affiliations: 
2013 Medical Sciences University of South Florida, Tampa, FL, United States 
Area:
Pharmacology, Pharmacy
Tree Info Grants Similar researchers PubMed Report error

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Jain P, Badger DB, Liang Y, Gebhard AW, Santiago D, Murray P, Kaulagari SR, Gauthier TJ, Nair R, Kumar M, Guida WC, Hazlehurst LA, McLaughlin ML. Bioactivity improvement via display of the hydrophobic core of HYD1 in a cyclic β-hairpin-like scaffold, MTI-101. Peptide Science (Hoboken, N.J.). 113: e24199. PMID 35859761 DOI: 10.1002/pep2.24199  0.539
2013 Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA. MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma. Molecular Cancer Therapeutics. 12: 2446-58. PMID 24048737 DOI: 10.1158/1535-7163.Mct-13-0310  0.644
2013 Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, et al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. Journal of Medicinal Chemistry. 56: 3768-82. PMID 23600925 DOI: 10.1021/Jm301234K  0.52
2012 Nair RR, Gebhard AW, Emmons MF, Hazlehurst LA. Emerging strategies for targeting cell adhesion in multiple myeloma. Advances in Pharmacology (San Diego, Calif.). 65: 143-89. PMID 22959026 DOI: 10.1016/B978-0-12-397927-8.00006-3  0.568
2012 Gebhard AW, Nair RR, Emmons M, Jain PR, Becker A, Koomen J, Schonbrunn E, Sullivan DM, McLaughlin ML, Hazlehurst LA. Mti-101 (cyclized HYD1) Binds to CD44 and Induces Necrotic Cell Death in Multiple Myeloma Blood. 120: 4022-4022. DOI: 10.1182/Blood.V120.21.4022.4022  0.614
2011 Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype. Molecular Cancer Therapeutics. 10: 2257-66. PMID 21980133 DOI: 10.1158/1535-7163.Mct-11-0149  0.633
2011 Gebhard AW, Emmons MF, Argilagos RF, McLaughlin M, Koomen J, Cress AE, Hazlehurst LA. Abstract 3628: The forced interaction of α4 integrin and CD44 by the novel peptide HYD1 may be a determinant of HYD1-induced cell death in multiple myeloma Cancer Research. 71: 3628-3628. DOI: 10.1158/1538-7445.Am2011-3628  0.511
2011 Emmons MF, Gebhard A, Mclaughlin M, Cress A, Hazlehurst L. Abstract 1523: α4 integrin expression is a determinant for activity of the integrin antagonist HYD1 in multiple myeloma cell lines and patient specimens Cancer Research. 71: 1523-1523. DOI: 10.1158/1538-7445.Am2011-1523  0.603
Show low-probability matches.